Highest-materiality recent filing
Strata Critical Medical Q2 revenue $72.5M (+60.7% YoY); net loss $(10.5)M
Revenue $72.5M, up 60.7% YoY; Clinical segment contributed $24.3M vs. zero in prior year.
William A. Heyburn re-elected with 46,050,902 for, 505,421 withhold, 12,687,496 broker non-votes.
Strata Critical Medical Q1 revenue up 87% to $67.4M; net income $2.4M vs prior loss
Revenue $67.4M (up 87.4% YoY); net income from cont. ops $2.4M vs loss of $1.6M YoY.
Strata Critical Medical Q4 revenue up 83.5% YoY to $66.8M; raises FY2026 guidance
Q4 2025 revenue $66.8M (+83.5% YoY); logistics revenue up 35.3% to $49.2M.
Strata Critical Medical secures $30M ABL credit facility from JPMorgan for acquisitions
Entered Credit Agreement for up to $30M revolving ABL facility, expandable to $50M subject to conditions.
Strata Critical Medical appoints Will Cook to board of directors
William L. Cook III appointed as Class I director effective Dec 2, 2025; board expanded from eight to nine directors.
Strata Critical Medical amends 8-K to include Keystone financials; acquisition closed
Acquisition of Keystone Perfusion Services closed Sep 16, 2025; all equity interests acquired.
Strata Critical Medical Q3 revenue up 36.7% to $49.3M; net loss widens to $9.7M
Revenue $49.3M, up 36.7% YoY; organic growth 29.0% excluding Keystone acquisition.
Strata completes $124M acquisition of Keystone Perfusion, updates 2025 guidance
Total upfront consideration of $124M (88% cash, 12% stock) at ~9x Keystone's estimated 2025 Adjusted EBITDA of ~$13M.
Strata Critical Medical Board sets annual say-on-pay votes until 2031
Stockholders voted for annual say-on-pay frequency at May 6, 2025 meeting.
Strata Critical Medical appoints Co-CEOs Tomkiel and Heyburn, approves $550K salary and PSUs
Melissa Tomkiel and William Heyburn became Co-CEOs effective Aug 1, 2025, retaining General Counsel and CFO roles respectively.
Completed sale of Passenger business to Joby Aero on Aug 29; received ~$76M in 5.3M Joby shares, plus up to $35M earnout and $10M holdbacks.
Blade Air Mobility Q2 net loss narrows to $3.7M; sells Passenger division to Joby for up to $125M
Q2 net loss improved $7.6M YoY to $(3.7)M; Adjusted EBITDA $3.2M vs $0.96M YoY.
Blade sells passenger division to Joby for up to $125M; to rebrand as Strata
Up to $125M consideration (cash or Joby stock): $90M at close plus up to $35M earnout tied to performance and retention.
Revenue $54.3M (+5.4% YoY); excluding exited Canada, up 10.9%.
Blade Air Mobility annual meeting elects directors, ratifies auditor, approves say-on-pay
Three Class I directors elected: John Borthwick (39.3M for, 6.4M withhold), Reginald Love (28.7M for, 17.0M withhold), Edward Philip (43.5M for, 2.2M withhold).
Blade Air Mobility Q4 revenue up 14.5% to $54.4M; Net loss narrows 71% YoY
Q4 revenue $54.4M (+14.5% YoY); net loss improved 71% to $(9.8)M from $(33.9)M.
Blade Air Mobility Q3 revenue $74.9M (+4.8%); net loss $(2.0)M; Adj EBITDA $4.2M
Revenue $74.9M, up 4.8% YoY; gross margin improved 520 bps to 19.3%.
Blade Air Mobility Q2 net loss narrows to $11.3M; first public Q2 with positive Adj. EBITDA $1.0M
Net loss of $11.3M improved $0.9M YoY; revenue $67.9M up 11.4% YoY.
Blade Q1 net loss narrows to $4.2M; Medical revenue record $36M, up 34.6% YoY
Total Q1 revenue of $51.5M, up 13.8% YoY; Medical segment revenue hit a record $36.0M.
Blade Air Mobility stockholders elect directors and ratify auditor at 2024 annual meeting
Susan Lyne elected as Class III director with 28,648,946 for, 8,168,466 withheld; Robert Wiesenthal with 30,585,817 for, 6,231,595 withheld.
Blade Air Mobility dismisses Marcum, appoints Deloitte as auditor for FY2024
Audit committee dismissed Marcum LLP on March 19, 2024; no disagreements on accounting or auditing matters.
Blade Air Mobility announces up to $20M share repurchase program; expects FY2024 adj. EBITDA profit
Board authorized repurchase of up to $20M of Class A common stock; program effective through March 31, 2025.
Blade Q4 revenue up 24.5% to $47.5M; guides for 2024 Adj. EBITDA profitability
Q4 revenue $47.5M (+24.5% YoY); full year revenue $225.2M (+54.1%).
Blade Air Mobility reports Q3 revenue up 56% to $71.4M; net income $0.3M
Revenue $71.4M (+56% YoY); net income $0.3M vs loss of $9.2M in Q3 2022.
Blade Q2 revenue $61M (+71%), medical $34.4M (+99%), net loss $12.2M
Q2 revenue $61.0M (+71% YoY); medical revenue $34.4M (+99% YoY, +29% sequentially).
Blade Q1 revenue up 70% to $45.3M; Flight Profit +145% to $7.2M
Short Distance revenue rose 148% YoY, driven by Blade Europe acquisition, Canada improvement, and Airport demand.
Blade Air Mobility holds annual meeting; elects three Class II directors and ratifies auditor
Stockholders elected Eric Affeldt, Andrew Lauck, and Kenneth Lerer as Class II directors for terms expiring at 2026 annual meeting.
Blade Air Mobility expands board to 9, appoints Lauck (RedBird) and Borthwick as directors
Board expanded from 7 to 9 members; Andrew Lauck (RedBird Capital) and John Borthwick (Betaworks) appointed as directors effective March 27, 2023.
Blade Q4 revenue $38.1M (+55% YoY); FY revenue $146.1M (+118%)
Q4 revenue $38.1M, up 55% YoY; FY revenue $146.1M, up 118% YoY.
Delaware Court validates Blade's capitalization under Section 205
Court of Chancery approved petition on Feb 27, 2023, validating Second Amended and Restated Certificate of Incorporation.
Blade Air Mobility files Delaware petition to validate stock increase; hearing Feb 27
On Feb 8, 2023, Blade filed a Section 205 petition with the Delaware Court of Chancery to validate its 2021 increase in authorized Class A common stock from 100M to 400M shares.
Blade revenue jumps to $24.6M in transition period; net income positive on warrant gain
Revenue $24.6M for three months ended Dec 31, 2021, up from $8.0M in prior-year period.
Blade Air Mobility Q3 revenue up 125% to $45.7M; Flight Profit up 108%
Revenue $45.7M (+125% YoY); Short Distance up 52%, MediMobility up 801%.
Blade completes €47.8M acquisition of Monacair, Héli Sécurité, Azur
Completed acquisition of commercial passenger transport activities of Monacair, Héli Sécurité, and Azur.
Blade Q2 revenue up 175% to $35.6M; net income $8.4M vs loss year ago
Total revenue $35.6M, up 175% YoY; MediMobility revenue $17.2M (+1,013%) driven by Trinity acquisition.
Purchase price €48M (US$50M) for asset-light commercial activities of Monacair, Héli Sécurité, and a third operator.
Blade Q1 revenue up 187% to $26.6M; net loss widens to $11.0M
Total revenue $26.6M, +187% YoY; MediMobility and Jet revenue $22.1M, +186%.
Blade Air Mobility annual meeting elects directors, ratifies auditor
Class I directors Reginald Love (35.5M for) and Edward Philip (33.6M for) elected to board.
Blade Q4 revenue $24.6M (+208% YoY); net income $0.8M; FY21 rev $67.2M
Q4 revenue $24.6M, up 208% YoY; Short Distance $6.2M (+191%); MediMobility & Jet $18.0M (+227%).
Board changes fiscal year from Sept 30 to Dec 31; abbreviates FY2021
Effective immediately, fiscal year end changed from September 30 to December 31.
Blade Q4 revenue up 144% to $20.3M; full-year $50.5M; acquires Trinity Air and Helijet
Q4 revenue $20.3M (+144% YoY, +28% vs pre-covid 2019); full-year revenue $50.5M (+116% YoY, +62% vs FY2019).
Blade pays $12M for exclusive rights to Helijet's scheduled passenger business in Canada
Deal includes exclusive rights to Helijet's scheduled flights and heliport terminals in Vancouver, Victoria, Nanaimo.
Blade Air Mobility appoints Reggie Love to board replacing David Zaslav
Reginald Love appointed independent director effective Sep 22, 2021; Class I director term expiring at next annual meeting.
Blade completes acquisition of Trinity Air Medical for ~$23M upfront
Closed on Sept 15, 2021; pays ~$23M upfront plus contingent earn-out based on EBITDA growth over 3 years.
Upfront purchase price of $23.1M in cash; potential earn-out based on EBITDA growth over three years.
Blade Air Mobility Q3 revenue up 277% to $13.0M; net loss widens to $24.3M on warrant adjustments
Revenue $13.0M (+277% YoY, +73% vs pre-COVID Q3 2019).
On March 27, 2023, the Board appointed John Borthwick and Andrew Lauck as independent directors of the Company, effective as of March 27, 2023.
On March 27, 2023, the Board appointed John Borthwick and Andrew Lauck as independent directors of the Company, effective as of March 27, 2023.
On September 22, 2021, the Board of Directors (the “Board”) of Blade Air Mobility, Inc. (the “Company”) appointed Reginald Love as an independent director of the Company, effective as of September 22, 2021.
Mr. Love will replace David Zaslav as a Class I director, upon Mr. Zaslav’s resignation from the Board effective September 22, 2021.
Max materiality 0.90 · Median 0.65 · Most common event earnings